Gene therapy: Charting a future course - Summary of a national institutes of health workshop, April 12, 2013

Human Gene Therapy

Volumn 25, Issue 6, 2014, Pages 488-497

  O'Reilly, Marina ^a   Federoff, Howard J ^b   Fong, Yuman ^c   Kohn, Donald B ^d   Patterson, Amy P ^a   Ahmed, Nabil ^e   Asokan, Aravind ^f   Boye, Shannon E ^g   Crystal, Ronald G ^h   De Oliveira, Satiro ^d   Gargiulo, Linda ^a   Harper, Scott Q ⁱ   Ikeda, Yasuhiro ^j   Jambou, Robert ^a   Montgomery, Maureen ^a   Prograis, Lawrence ^k   Rosenthal, Eugene ^a   Sterman, Daniel H ^l   Vandenberghe, Luk H ^m   Zoloth, Laurie ⁿ   Abedi, Mehrdad ^o   Adair, Jennifer ^p   Adusumilli, Prasad S ^q   Goins, William F ^r   Gray, Jhanelle ^s   Monahan, Paul ^f   Popplewell, Leslie ^c   Sena Esteves, Miguel ^t   Tannous, Bakhos ^u   Weber, Thomas ^v   Wierda, William ^w   Gopal Srivastava, Rashmi ^x   McDonald, Cheryl L ^y   Rosenblum, Daniel ^x   Corrigan Curay, Jacqueline ^a   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CENTER FOR CELL AND GENE THERAPY   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j MAYO CLINIC   (United States)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^l HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p Fred Hutchinson Cancer Research Center   (United States)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r UNIVERSITY OF PITTSBURGH   (United States)

^s H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^t UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^u MASSACHUSETTS GENERAL HOSPITAL   (United States)

^v MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^w UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^x NATIONAL INSTITUTES OF HEALTH   (United States)

^y NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CELL PROTEIN; COMPLEMENTARY DNA; GENE THERAPY AGENT; GENOMIC DNA; GUANYLATE CYCLASE; GUANYLATE CYCLASE 1; IMMUNOMODULATING AGENT; INTERFERON; LENTIVIRUS VECTOR; MICRORNA; NEW DRUG; PARVOVIRUS VECTOR; PLASMID DNA; RECOMBINANT DNA; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ADENO ASSOCIATED VIRUS; ANTIGEN ANTIBODY COMPLEX; BIOSAFETY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; EX VIVO STUDY; EYE DISEASE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; HEMATOPOIETIC STEM CELL; HEMOPHILIA; HUMAN; IMMUNE DEFICIENCY; INTERPERSONAL COMMUNICATION; LONG TERM CARE; MEDICAL ETHICS; MUSCLE DISEASE; MUSCULAR DYSTROPHY; NATIONAL HEALTH ORGANIZATION; NEUROLOGIC DISEASE; NONHUMAN; PLURIPOTENT STEM CELL; RETINA DEGENERATION; RETROVIRUS; REVIEW; RISK BENEFIT ANALYSIS; RNA INTERFERENCE; SCIENTIST; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WORKSHOP; ANIMAL; CONTINUING EDUCATION; ECONOMICS; ETHICS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LEGISLATION AND JURISPRUDENCE; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; UNITED STATES;

ANIMALS; EDUCATION, CONTINUING; GENETIC RESEARCH; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; TRANSDUCTION, GENETIC; UNITED STATES;

EID: 84902956982     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.045     Document Type: Review

References (47)

1. Aiuti, A., Cattaneo, F., Galimberti, S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 448-458.
2. Asokan, A., and Samulski, R.J. (2013). An emerging adenoassociated viral vector pipeline for cardiac gene therapy. Hum. Gene Ther. 24, 906-913.
3. Asokan, A., Schaffer, D., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699-708.
4. Booth, C., Gaspar, H.B., and Thrasher, A. (2011). Gene therapy for primary immunodeficiency. Curr. Opin. Pediatr. 23, 659-666.
5. Boye, S.E., Boye, S.L., Pang, J., et al. (2010). Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One 5, e11306.
6. Boye, S.L., Conlon, T., Erger, K., et al. (2011). Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest. Ophthalmol. Vis. Sci. 52, 7098-7108.
7. Boye, S.E., Alexander, J.J., Boye, S.L., et al. (2012). The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum. Gene Ther. 23, 1101-1115.
8. Boye, S.L., Peshenko, I.V., Huang, W.C., et al. (2013). AAVmediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum. Gene Ther. 24, 189-202.
9. Candotti, F., Shaw, K.L., Muul, L., et al. (2012). Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120, 3635-3646.
10. Davila, M., Riviere, I., Wang, X., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in a B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25.
11. Davis, P. (2012). An unparalleled engine for discovery and clinical introduction: the clinical and translational science awards and gene therapy. Hum. Gene Ther. 23, 251-253.
12. Deakin, C.T., Alexander, I.E., and Kerridge, I. (2009). Accepting risk in clinical research: is the gene therapy field becoming too risk-averse? Mol. Ther. 17, 1842-1848.
13. De Oliveira, S.N., Ryan, C., Giannoni, F., et al. (2013). Modification of hematopoietic stem/progenitor cells with CD19- specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum. Gene Ther. 24, 824-839.
14. DiStasi, A., Tey, S.-K., Dotti, G., et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683.
15. Dyka, F., Boye, S.L., Chiodo, V., et al., (2014). Dual adenoassociated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. Hum. Gene Ther. Methods 25, 166-177.
16. Eshhar, Z., Waks, T., Gross, G., et al. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720-724. (Pubitemid 23028937)
17. Fischer, A., Hacein-Bey-Abina, S., and Cavazana-Calvo, M. (2013). Gene therapy of primary T cell immunodeficiencies. Gene 525, 170-173.
18. Frantz, S. (2011). Engineered T-cell therapy shows efficacy in blood cancer. Nat. Biotechnol. 29, 853-855.
19. Gerdemann, U., Katari, U., Papadopoulou, A., et al. (2013). Safety and clinical efficacy of rapidly-generated trivirus- directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol. Ther. 21, 2113-2121.
20. Giannoni, F., Hardee, C.L., Wherley, J., et al. (2013). Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/ progenitor cells. Mol. Ther. 21, 1044-1054.
21. Gradaz, Z., Hegde, M., Byrd, T., et al. (2013). TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy, Mal. Ther. Nuc. Acids. 2, e105.
22. Grupp, S., Kalos, M., Barrett, D., et al. (2013.) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
23. Hacein-Bey-Abina, S., Hauer, J., Lim, A., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364.
24. Hauswirth, W., Aleman, T., Kaushal, S., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990.
25. Hegde, M., Corder, A., Chow, K., et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21, 2087-2101.
26. Jacobson, S.G., Cideciyan, A.V., Peshenko, I.V., et al. (2013). Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum. Mol. Genet. 22, 168-183.
27. Kaminsky, S., Rosengart, T., Rosenberg, J., et al. (2013). Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Hum. Gene Ther. 24, 948-963.
28. Kimmelman, J. (2009). Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer. Mol. Ther. 17, 1838-1839.
29. Kudva, Y., Ohmine, S., Greder, L., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Trans. Med. 1, 451-461.
30. Liu, J., Wallace, M., Garwick-Coppens, S., et al. (2014). RNAimediated gene silencing of mutant myotilin improves myopathy in LGMD1A mice. Mol. Ther. Nucleic Acids 3, e160.
31. Lopes, V.S., Boye, S.E., Louie, C.M., et al. (2013). Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther. 20, 824-833.
32. Maguire, A., Simonelli, F., Pierce, E., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. (Pubitemid 351724453)
33. Mukherjee, S., and Thrasher, A. (2013). Gene therapy for PIDs: progress, pitfalls, and prospects. Gene 525, 174-181.
34. Nathwani, A.C., Tuddenham, E., Rangarajan, S., et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
35. Porter, D., Levine, B., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
36. Pule, M., Finney, H., and Lawson, A., et al. (2003). Artificial T cell receptors. Cytotherapy 5, 211-226.
37. Pule, M., Savoldo, B., Myers, G.D., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270.
38. Romero, Z., Urbinati, F., Geiger, S., et al. (2013). b-globin gene transfer to human bone marrow for sickle cell disease. J. Clin. Invest. 123, 3317-3330.
39. Savoldo, B., Ramos, C., Liu, E., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826.
40. Sondhi, D., Johnson, L., Purpura, K., et al. (2012). Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. Methods 23, 324-335.
41. Stroes, E., Nieman, M., Meulenberg, J., et al. (2008). Intramuscular administration of AAV1-lipoprotein lipaseS447 · lowers triglycerides in lipoprotein lipase-deficient patients. Arterioschler. Thromb. Vasc. Biol. 28, 2303-2304.
42. Thatava, T., Kudva, Y., Edukulla, R., et al. (2013). Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol. Ther. 21, 228-239.
43. Till, B., Jensen, M., Wang, J., et al. (2013). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1 BB domains: pilot clinical trial results. Blood 119, 3940-3950.
44. Vanden Driessche, T., and Chuah, M.K. (2012). Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B. Hum. Gene Ther. 23, 4-6.
45. Vanneman, M., and Dranoff, G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251.
46. Wade, N. (2011). Treatment of blood disease is gene therapy landmark. New York Times, December 11.
47. Zallin, D. (2000). US gene therapy in crisis. Trends Genet. 6, 272-275.